Clinical Trials

827 enrolled 34 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04697628 2026-02-24

innovaTV 301

502 enrolled 18 charts 1 FDA

Uterine Cervical Neoplasms

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT01844986 2025-12-10

SOLO-1

450 enrolled 18 charts 1 FDA

Phase 2 Active not recruiting

Pathologic Complete Response, Ovarian Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

1,609 enrolled 4 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04209855 2025-08-27

MIRASOL

453 enrolled 18 charts 1 FDA

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

327 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

381 enrolled 1 FDA

265 enrolled 25 charts 1 FDA

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase 2 Completed

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Phase 1 Active not recruiting

272 enrolled 1 FDA

DermatologicGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Small Cell

NCT03737643 2025-01-29

DUO-O

1,407 enrolled 1 FDA

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT04625270 2025-01-29

RAMP 201

225 enrolled 1 FDA

Ovarian Neoplasms

NCT04296890 2024-08-07

SORAYA

106 enrolled 14 charts 1 FDA

102 enrolled 20 charts 1 FDA

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03438396 2023-07-25

A Trial of Tisotumab Vedotin in Cervical Cancer

Phase 2 Completed

Uterine Cervical Neoplasms

NCT01968213 2023-06-09

ARIEL3

564 enrolled 18 charts 1 FDA

463 enrolled 15 charts 1 FDA

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02354586 2022-09-15

QUADRA

Phase 2 Completed

Ovarian Neoplasms

NCT03180307 2022-02-04

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

140 enrolled 11 charts 1 FDA